|  |  |
| --- | --- |
|  | **NHS Prescription Services**  Bridge House  152 Pilgrim Street  Newcastle upon Tyne  NE1 6SN  0845 850 0001  Email:[nhsbsa.prescriptionservices@nhsbsa.nhs.uk](mailto:nhsbsa.prescriptionservices@nhsbsa.nhs.uk)  Website:[www.nhsbsa.nhs.uk](http://www.nhsbsa.nhs.uk)  18 Mar 2024 |
|  |

VERSION 3.2.0

Dear dm+d User,

[**VMP ‘<Drug Form>’ coded attribute in dm+d – Advanced notice of Phase 2 changes**](https://nhsengland.kahootz.com/t_c_home/viewBlogArticle?articleID=982361&nextURL=%2Ft_c_home%2FviewBlog%3Fblogid%3D50136)

Following on from the Phase 1 drug form changes which appeared in the dm+d data on Monday 20 November 2023, we are providing **advanced notification** of the proposed dates for Phase 2 drug form changes.

The new Phase 2 drug forms were released in the TRUD extract Monday 15 January 2024, however these descriptions and codes will not be attached to VMPs until the dates confirmed (see below).

Please note that the new form: ‘42550811000001100 I Powder and solvent for intraocular instillation irrigation’ has been renamed ‘Powder and solvent for solution for intraocular irrigation’. The assigned SNOMED UK extension code remains the same.

Please note that information about changes in Phase 2 to the existing forms of ‘Gastroenteral liquid’ and ‘Powder for gastroenteral liquid’ has been added under ‘**Quarter 1 2024**’ of ‘the ‘[Timeframes](https://digital.nhs.uk/services/terminology-and-classifications/uk-medicines-terminology-futures/changes-to-digital-terminologies/updating-the-nhs-dm-d-drug_form-coded-attribute-within-the-vmp-concept-class#timeframes)’ section of our webpage

Updates to the following drug forms are being planned to take place in the dm+d data:

|  |  |  |
| --- | --- | --- |
| **Dates** | **Phase 2 Drug Form Changes** | **Confirmation of change** |
| **Monday 29 January 2024** | * Implant, * **Implantation suspension** * **Irrigation** * **Irrigation solution** | Live in dm+d extract 29 January 2024 |
| **Monday 12 February 2024**  AND  **Monday 19 February 2024** | * **Liquid**\* * **Powder\***   ***\*Excluding oral and gastroenteral powders and liquids*** | **Majority of changes live in dm+d extract 12 February 2024**  **AND**  **Remaining changes live in dm+d extract 19 February 2024** |
| **Monday 11 March 2024**  AND  **Monday 18 March 2024** | * **Oral and gastroenteral powders** * **Oral and gastroenteral liquids** | **Majority of changes live in dm+d extract 11 March 2024**  **AND**  **Remaining changes live in dm+d extract 18 March 2024. All Phase 2 Drug Form changes are now complete** |

More detailed information, including what new updated drugs forms will be available, are published on the webpage [Updating the NHS dm+d ‘<DRUG\_FORM>’ coded attribute within the Virtual Medicinal Product concept class - NHS Digital](https://digital.nhs.uk/services/terminology-and-classifications/uk-medicines-terminology-futures/changes-to-digital-terminologies/updating-the-nhs-dm-d-drug_form-coded-attribute-within-the-vmp-concept-class)

Information advising how technical queries might be written to identify VMP Drug Form changes from either TRUD or NHSE Terminology Server can be found here: [Identifying updates to the VMP <DRUG\_FORM> code attribute in Dictionary of medicines and devices (dm+d) - NHS Digital](https://digital.nhs.uk/services/terminology-and-classifications/uk-medicines-terminology-futures/changes-to-digital-terminologies/identifying-updates-to-the-vmp-drug_form-code-attribute-in-dm-d)

Should you have any specific questions about this work please email: [nhsdigital.ukmeds@nhs.net](mailto:nhsdigital.ukmeds@nhs.net)

**Advanced Notice: Rivaroxaban (Xarelto® 1mg/ml granules for oral suspension) Update - dm+d VMPP/AMPP Pack Sizes to be Updated to Reflect the Volumes of Water added for Reconstitution**

A dm+d issue has been raised regarding concerns that the volumes listed in the Drug Tariff and dm+d for Xarelto 1mg/ml granules for oral suspension do not reflect the actual usable volumes of the suspension after reconstitution which are not defined in the SmPC and packaging.

The dm+d Content Committee discussed this at length in a recent meeting. The Committee unanimously agreed that, for this product, the VMPPs/AMPPs will be updated to be based on the volumes of water added for reconstitution. This is the most pragmatic way forwards in the absence of final reconstituted volumes being categorically published in the SmPC.

Similarly, to plans previously communicated via this TRUD platform in June 2023, from 1st April 2024 the pack sizes in dm+d will reflect the volumes of water added for reconstitution (rather than the bottle sizes) as follows:

**VMP**: Rivaroxaban 1mg/ml granules for oral suspension sugar free

|  |  |
| --- | --- |
| **Pack size concepts to be made INVALID** | **REPLACEMENT pack size concepts** |
| VMPP: 100ml (bottle size) | VMPP: 50ml (volume of water added for reconstitution) |
| VMPP: 250ml (bottle size) | VMPP: 100ml (volume of water added for reconstitution) |

**AMP**: Xarelto 1mg/ml granules for oral suspension (Bayer Plc)

|  |  |
| --- | --- |
| **Pack size concepts to be made INVALID** | **REPLACEMENT pack size concepts** |
| AMPP: 100ml (bottle size) | AMPP: 50ml (volume of water added for reconstitution) |
| AMPP 250ml (bottle size) | AMPP 100ml (volume of water added for reconstitution) |

Note – the larger bottle size allows sufficient space for mixing the granules and water.

**Part VIIIA of the NHS England and Wales Drug Tariff** also includes an entry that refers to the 250ml pack size and this will similarly be updated from 250ml to 100ml from 1st April 2024.

**NHS dm+d Editorial Policy —** an updated version will be published in the public domain over the next few days with wording to provide more clarity around authoring of oral products requiring reconstitution.

**Clinical system suppliers should** update their systems in a timely manner and support their users. Please be mindful that there might be a time lag between prescribing and dispensing system updates. Also, if there is any confusion for a few weeks after the update, dispensers and prescribers may need to link in with each other to ensure that prescriptions are in line with and reflect the **REPLACEMENT pack size concepts** in the tables above.

Should you have any further enquiries, please email [dmdenquiries@nhsbsa.nhs.uk](mailto:dmdenquiries@nhsbsa.nhs.uk)

**Monthly dm+d Supplier Workshop**

NHS England hosts a monthly workshop for IT system suppliers to discuss dm+d content and implementation queries.  It is an opportunity to speak with colleagues from NHS England and the NHSBSA who manage the terminology.

If you are a system supplier who is interested in joining the group, please contact [medicinestandards@nhs.net](mailto:medicinestandards@nhs.net) for more information.

**DHSC require these concepts to be made available and visible (similar to licensed medicines) in prescribing and dispensing systems for the time being.**

|  |  |  |  |
| --- | --- | --- | --- |
| **Specials/Imports added at request of DHSC to mitigate shortages in the supply chain** | | | |
| **AMP Name** | **AMP SNOMED Code** | **Import/Special** | **dm+d extract date** |
| Desmopressin 150micrograms/dose nasal spray | 38955011000001100 | Imported | 14/09/2020 |
| Desmopressin 150micrograms/dose nasal spray | 38996011000001101 | Special Order | 21/09/2020 |
| Capsaicin 0.025% cream | 41539411000001105 | Imported | 27/03/2023 |
| Capsaicin 0.075% cream | 41540711000001105 | Imported | 27/03/2023 |
| Pethidine 50mg tablets | 42161611000001107 | Imported (United States) | 14/08/2023 |
| Permethrin 5% cream | 42243511000001101 | Imported | 18/09/2023 |
| Vyvanse 30mg capsules | 42409311000001100 | Imported | 13/11/2023 |
| Vyvanse 40mg capsules | 42409611000001105 | Imported | 13/11/2023 |
| Vyvanse 50mg capsules | 42409811000001109 | Imported | 13/11/2023 |
| Vyvanse 70mg capsules | 42410011000001109 | Imported | 13/11/2023 |
| Lisdexamfetamine 30mg capsules | 42415211000001108 | Imported | 20/11/2023 |
| Lisdexamfetamine 40mg capsules | 42415411000001107 | Imported | 20/11/2023 |
| Lisdexamfetamine 50mg capsules | 42415611000001105 | Imported | 20/11/2023 |
| Lisdexamfetamine 70mg capsules | 42415811000001109 | Imported | 20/11/2023 |
| Bumetanide 5mg tablets | 42440611000001105 | Imported | 27/11/2023 |
| Co-trimoxazole 40mg/200mg/5ml oral suspension sugar free | 42440811000001109 | Imported | 27/11/2023 |
| Disopyramide 250mg modified-release tablets | 42441311000001105 | Imported | 27/11/2023 |
| Griseofulvin 125mg tablets | 42441511000001104 | Imported (United States) | 27/11/2023 |
| Griseofulvin 500mg tablets | 42441811000001101 | Imported (United States) | 27/11/2023 |
| Lamotrigine 5mg dispersible tablets sugar free | 41526311000001107 | Imported | 27/11/2023 |
| Rasagiline 1mg tablets | 42442211000001109 | Imported | 27/11/2023 |
| Rifampicin 150mg capsules | 42442611000001106 | Imported | 27/11/2023 |
| Fluticasone 400microgram/unit dose nasal drops | 42490511000001100 | Imported (Spain) | 11/12/2023 |
| Dicycloverine 10mg/5ml oral solution | 42491411000001108 | Imported (United States) | 11/12/2023 |
| Diazepam 2mg/5ml oral suspension sugar free | 42495311000001104 | Special Order | 11/12/2023 |
| Hydrogen peroxide 3% solution | 42510811000001109 | Imported | 18/12/2023 |
| Lisdexamfetamine 20mg capsules | 42640311000001103 | Imported | 19/02/2024 |
| Lisdexamfetamine 60mg capsules | 42640611000001108 | Imported | 19/02/2024 |
| Oxcarbazepine 60mg/ml oral suspension sugar free | 42640911000001102 | Special Order | 19/02/2024 |
| Oxcarbazepine 150mg tablets | 42641111000001106 | Imported | 19/02/2024 |
| Nadolol 80mg tablets | 42641311000001108 | Imported | 19/02/2024 |
| Phosphate Phebra effervescent tablets | 42641611000001103 | Imported | 19/02/2024 |
| Methadone 5mg tablets | 42641811000001104 | Imported | 19/02/2024 |
| Salbutamol 2.5mg/2.5ml nebuliser liquid unit dose vials | 42642011000001102 | Imported | 19/02/2024 |
| Salbutamol 5mg/2.5ml nebulizer liquid unit dose vials | 42642211000001107 | Imported | 19/02/2024 |

**Invalidations**

The following concepts have been invalidated.

These products were added erroneously. The company have presented new information, resulting in these products now having a ‘branding’ and were therefore reauthored.

|  |  |
| --- | --- |
| **Concept to be made Invalid** | **Replacement concepts** |
| **VMP** Ispaghula husk 3.5g effervescent granules sachets gluten free sugar free (VMP not being invalidated) | **VMP** N/A |
| **VMP SNOMED ID** 38897111000001108 | **VMP SNOMED ID** N/A |
| **VMPP** 30 sachet (not being invalidated) | **VMPP** N/A |
| **VMPP SNOMED ID** 3249811000001107 | **VMPP SNOMED ID** N/A |
| **AMP** Ispaghula husk 3.5g effervescent granules sachets gluten free sugar free (TriOn Pharma Ltd) | **AMP** AAA Ispaghula husk 3.5g effervescent granules sachets gluten free sugar free (TriOn Pharma Ltd) |
| **AMP SNOMED ID** 42030711000001105 | **AMP SNOMED ID** 42637811000001105 |
| **AMPP** 30 sachet | **AMPP** 30 sachet |
| **AMPP SNOMED ID** 42030811000001102 | **AMPP SNOMED ID** 42637911000001100 |

|  |  |
| --- | --- |
| **Concept to be made Invalid** | **Replacement concepts** |
| **VMP** Ispaghula husk 3.5g/dose effervescent granules gluten free sugar free (VMP not being invalidated) | **VMP** N/A |
| **VMP SNOMED ID** 3776211000001106 | **VMP SNOMED ID** N/A |
| **VMPP** 300 gram (not being invalidated) | **VMPP** N/A |
| **VMPP SNOMED ID** 42591811000001102 | **VMPP SNOMED ID** N/A |
| **AMP** Ispaghula husk 3.5g/dose effervescent granules gluten free sugar free (TriOn Pharma Ltd) | **AMP** AAA Ispaghula husk 3.5g/dose effervescent granules gluten free sugar free (TriOn Pharma Ltd) |
| **AMP SNOMED ID** 42591711000001105 | **AMP SNOMED ID** 42638011000001103 |
| **AMPP** 300 gram | **AMPP** 300 gram |
| **AMPP SNOMED ID** 42592011000001100 | **AMPP SNOMED ID** 42638111000001102 |

**Advance Notice of Invalidations**

None

dm+d Authoring Team